Reirradiation outcomes following salvage conventionally fractionated Gamma Knife stereotactic radiotherapy (SFGK) to recurrent primary non-glial brain tumors
Journal of Neuro-Oncology · 2026
DOI: 10.1007/s11060-026-05757-3 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Neuro-Oncology, 2026. Verfasst von Cristian Udovicich und 11 weiteren Autor:innen. Beteiligte Einrichtung: Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, ON, Canada. Hauptthemen laut MEDLINE: Radiosurgery, Salvage Therapy, Brain Neoplasms, Neoplasm Recurrence, Local. Die Arbeit nennt 19 Literaturangaben.
Abstract (Originalsprache)
PURPOSE: To evaluate the efficacy and safety of salvage conventionally fractionated Gamma Knife stereotactic radiotherapy (SFGK) reirradiation for recurrent, previously irradiated primary non-glial brain tumours. METHODS: Consecutive patients underwent SFGK from 2019 to 2024 for progressive, previously definitively irradiated primary intracranial tumours. The primary endpoint was local progression-free survival (LPFS). Secondary endpoints were overall survival (OS) and safety. RESULTS: Twenty-six patients (44 tumours) were treated. There were 34 meningiomas (77%), of which 28 were WHO Grade 2. The median time from prior radiotherapy was 50.4 months (IQR 19.7-86.8). The SFGK prescription dose was 50.4 Gy in 28 fractions in 37 tumors (84%). The median cumulative prescription EQD2 was 102.7 Gy (IQR 99.6-114.6) for those with one prior radiotherapy course. The median normal brain EQD2 was 99.2 Gy (97.9-117.5) for those with one prior radiotherapy course. The median follow-up was 18.1 months (IQR 10.5-28.2). Overall LPFS at 12 and 24 months was 91.0% (95% CI 73.6-97.2%) and 75.1% (95% CI 51.0-88.6%), respectively. OS at 12 and 24 months was 96.2% (95% CI 75.7-99.4%) and 83.2% (95% CI 54.8-94.6%), respectively. For the meningioma cohort, 12- and 24-month LPFS was 90.6% (95% CI 65.7-97.7%) and 74.1% (95% CI 42.7-90.0%), respectively. Grade 3 radionecrosis occurred in two patients (6.9%), one case of Grade 3 progressive intracranial hemorrhage (3.4%), and no Grade 4 or 5 events were observed. CONCLUSIONS: SFGK re-irradiation is feasible and well tolerated, achieving durable local control in recurrent non-glial brain tumours with few serious adverse events despite high cumulative doses.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, ON, Canada.
- Department of Radiation Oncology, University of Toronto, Toronto, ON, Canada.
- Department of Radiation Oncology, GenesisCare, Melbourne, Victoria, Australia.
- Department of Biostatistics, University Health Network, Toronto, ON, Canada.
- Division of Biostatistics, Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada.
- Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, ON, Canada. arjun.sahgal@sunnybrook.ca.
Zitieren
APA
Udovicich, C., Tseng, C. L., Detsky, J., Chen, H., Dinakaran, D., Soliman, H., Zeng, K. L., Ruschin, M., Yeboah, C., Holden, L., Atenafu, E. G., & Sahgal, A. (2026). Reirradiation outcomes following salvage conventionally fractionated Gamma Knife stereotactic radiotherapy (SFGK) to recurrent primary non-glial brain tumors. Journal of Neuro-Oncology. https://doi.org/10.1007/s11060-026-05757-3
Vancouver
Udovicich C, Tseng CL, Detsky J, Chen H, Dinakaran D, Soliman H, et al. Reirradiation outcomes following salvage conventionally fractionated Gamma Knife stereotactic radiotherapy (SFGK) to recurrent primary non-glial brain tumors. Journal of Neuro-Oncology. 2026. doi:10.1007/s11060-026-05757-3
BibTeX
@article{Udovicich2026,
author = {Udovicich, Cristian and Tseng, Chia-Lin and Detsky, Jay and Chen, Hanbo and Dinakaran, Deepak and Soliman, Hany and Zeng, K Liang and Ruschin, Mark and Yeboah, Collins and Holden, Lori and Atenafu, Eshetu G and Sahgal, Arjun},
title = {Reirradiation outcomes following salvage conventionally fractionated Gamma Knife stereotactic radiotherapy (SFGK) to recurrent primary non-glial brain tumors},
journal = {Journal of Neuro-Oncology},
year = {2026},
doi = {10.1007/s11060-026-05757-3}
}
EUVIMED